Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulant drugs: an update.

Hau C Kwaan1, Meyer M Samama

  • 1Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, 333 East Huron Street, Chicago, IL 60011-3008, USA. h-kwaan@northwestern.edu

Expert Review of Cardiovascular Therapy
|July 1, 2004
PubMed
Summary

New anticoagulant drugs offer improved efficacy and safety for treating thromboembolic disorders. However, challenges remain in developing ideal agents with specific antidotes and lower costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage.

Annals of clinical and translational neurology·2024
Same author

Corrigendum: Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapies.

Frontiers in immunology·2024
Same author

Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapies.

Frontiers in immunology·2023
Same author

SHock-INduced Endotheliopathy (SHINE): A mechanistic justification for viscoelastography-guided resuscitation of traumatic and non-traumatic shock.

Frontiers in physiology·2023
Same author

Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on "Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. <i>J. Clin. Med.</i> 2022, <i>11</i>, 860".

Journal of clinical medicine·2023
Same author

Emerging Use of Viscoelastography in Thrombosis and Hemostasis: A Challenge to Conventional Coagulation Tests?-Part II: The Use of Thromboelastography and Thromboelastometry in the Assessment of Clinical Disorders.

Seminars in thrombosis and hemostasis·2022

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Thromboembolic disorders necessitate effective anticoagulant therapy.
  • Existing anticoagulants have limitations, driving the need for improved agents.
  • Advances in understanding coagulation factors and thrombus structure enable targeted drug design.

Purpose of the Study:

  • To review recent advancements in anticoagulant drug development.
  • To highlight the characteristics and limitations of novel anticoagulant agents.
  • To discuss the ongoing challenges in creating an ideal anticoagulant.

Main Methods:

  • Review of scientific literature on new anticoagulant drugs.
  • Analysis of pharmacological properties, efficacy, and safety profiles.
  • Comparison of novel agents with conventional anticoagulants.

Main Results:

  • Newer anticoagulants, including lepirudin, fondaparinux, and ximelagatran, offer improved characteristics like oral administration and reduced monitoring.
  • These agents can target both surface-bound and fibrin-bound thrombin or Factor Xa.
  • Despite advancements, current drugs lack ideal properties, such as specific antidotes and lower cost.

Conclusions:

  • Novel anticoagulant drugs represent significant progress in managing thromboembolic disorders.
  • Further research is needed to develop agents that overcome existing limitations, including the absence of specific reversal agents and high costs.
  • The pursuit of an ideal anticoagulant with comprehensive benefits remains an ongoing challenge in pharmaceutical research.

Related Experiment Videos